Intec Pharma up 2% on advancement of Accordion Pill with Novartis

|About: Intec Pharma (NTEC)|By:, SA News Editor

Thinly traded micro cap Intec Pharma (NTEC +1.9%) is up on 80% higher volume in reaction to its announcement that its program with Novartis (NVS -3%) aimed at developing the Accordion Pill for an unnamed compound will proceed to a clinical pharmacokinetic study in H1 2019.

Previously: Intec nabs new U.S. patent protecting Accordion Pill technology; shares ahead 4% (May 24, 2017)

Subscribe for full text news in your inbox